Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD30 CAR-T in CD30+ Relapsed/Refractory Lymphoma
NCT05208853Phase 1Unknown
- Sponsor
- Zhejiang University
- Start
- Feb 2022
- Primary completion
- Feb 2022
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-CD30 chimeric antigen receptor T cells in CD30-positive lymphoma, sponsored by Zhejiang University. Primary endpoints: Maximum Tolerated Dose at 4 weeks and Adverse Events and Serious Adverse Events at 12 months. Status: unknown.
02
Drugs
anti-CD30 chimeric antigen receptor T cells
03
Conditions
CD30-positive lymphoma
Beyond the preview
Go deeper on NCT05208853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05208853.